119 results about "Nasopharyngeal Cancers" patented technology

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

Three kinds of tissues including cancer tissue, precancerosis and corresponding normal tissue are sliced up, dyed, marked, and positioned. Receptor holes are prepared by leading designed lattice array mould paper to paste on surface of wax block of receptor. Wax block with tissue core bar is prepared by using perforating needle and puncture needle for tissue. Common cancer such as lung cancer, nasopharyngeal carcinoma, oesophagus cancer etc. and having integrated clinical data and pathology features are selected. Through in situ hybridization, testing mRNA of relevant gene and expression of protein on tissue chip, consistent result between the invented product and traditional test is validated. In the product, cellular morphology is clear and even, and there is no fallen off tissue point. The invention is applicable to filter cancers, early diagnosis and forecasting prognosis.

The invention discloses an application of niclosamide or pharmaceutically-acceptable salts thereof in preparing anti-tumor drugs, which provides a candidate drug for tumor patients and may further improve the therapeutic effect and the prognosis to patients. The effectiveness of niclosamide or pharmaceutically-acceptable salts thereof on various tumor cells indicates that the composition may be used for treating various cancers such as cerebroma, genitourinary tumor, lymphatic system, stomach cancer, cancer of larynx, nasopharyngeal cancer, skin cancer, bone cancer, leukaemia, leukaemia, breast cancer, histiocytic lymphoma, non-small-cell lung cancer, small-cell lung cancer, lung adenocarcinoma, epidermoid cancer, pancreatic cancer, prostatic cancer, liver cancer and epithelial cell cancer.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2/M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.

The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis.

The invention belongs to the field of antineoplastic drug preparation and relates to novel application of polydatin to preparing the antineoplastic drugs. The invention also provides an antineoplastic drug, wherein the main active component of the antineoplastic drug is polydatin. In the invention, the proliferations of cells such as breast cancer, lung cancer, liver cancer, ovarian cancer, cervical cancer, nasopharyngeal cancer, leukemia and the like treated by the antineoplastic drug polydatin are all restrained obviously; a cell cycle analysis shows that the S phase in the cell cycle is retardant and cell apoptosis is induced; and the polydatin with low concentration has the effect of restraining the migration and the conglutination of a tumor cell. In the invention, while the antineoplastic drug polydatin increases the treatment effect of a malignant tumor and reduces the incidence rate of relapse and transfer of a tumor patient, the toxic and side effects are obviously reduced compared with the traditional clinical commonly used chemotherapeutic drugs, therefore, the lifetime of a malignant tumor patient is prolonged, and the life quality of the malignant tumor patient is improved.

The invention relates to a sustained-release implant for treating a solid tumor, which is characterized in that: the sustained-release implant contains an effective anticancer amount of bortezomib and sustained-release excipients. The solid tumor includes brain tumor, liver cancer, lung cancer, oesophagus cancer, gastric cancer, breast cancer, pancreatic cancer, thyroid cancer, nasopharyngeal cancer, ovarian cancer, endometrial cancer, cervical cancer, renal cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, skin cancer, head and neck cancer and primary or secondary cancer, caruncle or carcinosarcoma rooted at a peripheral nervous system, mucosa, glands, blood vessels, bone tissues and lymph nodes. The sustained-release excipients are mainly a biological polymer which is dissoluble and can be degraded and absorbed, in the degradation and absorption process of which carmustine is sustainedly released to part of the tumor, thus the entire toxicity of the carmustine is significantly reduced while an effective medicine consistency is maintained on part of the tumor. That the sustained-release implant is implanted inside part of the tumor can not only reduce the entire toxicity of the carmustine but also enhance the medicine consistency on part of the tumor, thereby increasing the curing effect of non-operative therapeutics such as chemotherapeutic drugs and radiotherapy.

The present invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor with anti-cancer activity. More particularly, this invention relates to an indirubin-3′-oxime derivative as potent cyclin dependent kinase inhibitor having excellent anti-cancer activity against human lung cancer cell, human fibro sarcoma cell, human colon cancer cell, human leukemia cell, human stomach cancer cell, human nasopharyngeal cancer cell and/or human breast cancer cell.

The invention provides Paris forrestii (Takht.) H. Li total saponin PFE-PT3 and monomer saponin combination PFE-PT65, and provides a pharmaceutical composition using the combination as an active ingredient, and application in the preparation of a drug for preventing or treating drug-resistant breast cancer and drug-resistant nasopharyngeal carcinoma. The Paris forrestii (Takht.) H. Li total saponin PFE-PT3 and monomer saponin combination PFE-PT65 has an obvious inhibiting effect on adriamycin-resistant human breast cancer MCF-7 / ADM cells, with a resistance index of less than 2, and has an obvious inhibiting effect on paclitaxel-resistant human nasopharyngeal carcinoma KBvin cell growth, with a resistance index of less than 2.

The invention discloses a ruthenium complex and application thereof. The cation part of the ruthenium complex is [Ru(phen)2(HIPMP)]<2+>, and the anion part is (ClO4)[-] or Cl[-]. The mononuclear ruthenium complex has favorable anticancer activities, and has obvious treatment effects on cervical cancer cells, liver cancer cells, lung cancer cells nasopharyngeal carcinoma cells and other cancers. The tumor cell apoptosis induction of the mononuclear ruthenium complex mainly relates to endogenous endoplasmic reticulum channels, and has important meanings for researching high-efficiency ruthenium antineoplastic drugs.